Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Sell
12
CSLLY Quote, Financials, Valuation and Earnings
Last price:
$86.16
Seasonality move
:
4.2%
Day range:
$85.63 - $86.48
52-week range:
$83.31 - $109.00
Dividend yield:
1.53%
P/E ratio:
32.13x
P/S ratio:
5.69x
P/B ratio:
4.81x
Volume:
75K
Avg. volume:
75K
1-year change:
-7.9%
Market cap:
$83.4B
Revenue:
$14.7B
EPS (TTM):
$2.73
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSLLY
CSL
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics
|
-- | -- | -- | -- | $9.00 |
|
IMMP
Immutep
|
-- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics
|
-- | -- | -- | -- | -- |
|
MESO
Mesoblast
|
$1.5M | -- | -100% | -- | $11.00 |
|
OPT
Opthea
|
-- | -- | -- | -- | $12.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSLLY
CSL
|
$86.16 | -- | $83.4B | 32.13x | $0.73 | 1.53% | 5.69x |
|
ATHE
Alterity Therapeutics
|
$3.42 | $9.00 | $29.9M | -- | $0.00 | 0% | 1.50x |
|
IMMP
Immutep
|
$1.93 | -- | $280.7M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics
|
$1.42 | -- | $6.2M | -- | $0.00 | 0% | -- |
|
MESO
Mesoblast
|
$17.30 | $11.00 | $2B | -- | $0.00 | 0% | 179.39x |
|
OPT
Opthea
|
$3.90 | $12.17 | $599.4M | -- | $0.00 | 0% | 2,492.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSLLY
CSL
|
37.73% | 0.591 | 10.82% | 0.87x |
|
ATHE
Alterity Therapeutics
|
-- | -4.982 | -- | -- |
|
IMMP
Immutep
|
-- | -0.152 | -- | -- |
|
KZIA
Kazia Therapeutics
|
-6.76% | 0.052 | 5.57% | 0.07x |
|
MESO
Mesoblast
|
-- | -0.629 | -- | -- |
|
OPT
Opthea
|
215.31% | 0.522 | 53.76% | 2.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSLLY
CSL
|
-- | -- | 8.85% | 14.06% | -- | -- |
|
ATHE
Alterity Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast
|
-- | -- | -- | -- | -- | -- |
|
OPT
Opthea
|
-- | -- | -669.85% | -- | -- | -- |
CSL vs. Competitors
-
Which has Higher Returns CSLLY or ATHE?
Alterity Therapeutics has a net margin of -- compared to CSL's net margin of --. CSL's return on equity of 14.06% beat Alterity Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL-- -- $29.9B ATHEAlterity Therapeutics-- -- -- -
What do Analysts Say About CSLLY or ATHE?
CSL has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics has an analysts' consensus of $9.00 which suggests that it could grow by 163.16%. Given that Alterity Therapeutics has higher upside potential than CSL, analysts believe Alterity Therapeutics is more attractive than CSL.
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL0 0 0 ATHEAlterity Therapeutics1 0 0 -
Is CSLLY or ATHE More Risky?
CSL has a beta of 0.750, which suggesting that the stock is 25% less volatile than S&P 500. In comparison Alterity Therapeutics has a beta of 0.655, suggesting its less volatile than the S&P 500 by 34.451%.
-
Which is a Better Dividend Stock CSLLY or ATHE?
CSL has a quarterly dividend of $0.73 per share corresponding to a yield of 1.53%. Alterity Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL pays 47.92% of its earnings as a dividend. Alterity Therapeutics pays out -- of its earnings as a dividend. CSL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or ATHE?
CSL quarterly revenues are --, which are smaller than Alterity Therapeutics quarterly revenues of --. CSL's net income of -- is lower than Alterity Therapeutics's net income of --. Notably, CSL's price-to-earnings ratio is 32.13x while Alterity Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL is 5.69x versus 1.50x for Alterity Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL5.69x 32.13x -- -- ATHEAlterity Therapeutics1.50x -- -- --
-
Which has Higher Returns CSLLY or IMMP?
Immutep has a net margin of -- compared to CSL's net margin of --. CSL's return on equity of 14.06% beat Immutep's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL-- -- $29.9B IMMPImmutep-- -- -- -
What do Analysts Say About CSLLY or IMMP?
CSL has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep has an analysts' consensus of -- which suggests that it could grow by 392.23%. Given that Immutep has higher upside potential than CSL, analysts believe Immutep is more attractive than CSL.
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL0 0 0 IMMPImmutep2 0 0 -
Is CSLLY or IMMP More Risky?
CSL has a beta of 0.750, which suggesting that the stock is 25% less volatile than S&P 500. In comparison Immutep has a beta of 2.197, suggesting its more volatile than the S&P 500 by 119.655%.
-
Which is a Better Dividend Stock CSLLY or IMMP?
CSL has a quarterly dividend of $0.73 per share corresponding to a yield of 1.53%. Immutep offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL pays 47.92% of its earnings as a dividend. Immutep pays out -- of its earnings as a dividend. CSL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or IMMP?
CSL quarterly revenues are --, which are smaller than Immutep quarterly revenues of --. CSL's net income of -- is lower than Immutep's net income of --. Notably, CSL's price-to-earnings ratio is 32.13x while Immutep's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL is 5.69x versus -- for Immutep. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL5.69x 32.13x -- -- IMMPImmutep-- -- -- --
-
Which has Higher Returns CSLLY or KZIA?
Kazia Therapeutics has a net margin of -- compared to CSL's net margin of --. CSL's return on equity of 14.06% beat Kazia Therapeutics's return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL-- -- $29.9B KZIAKazia Therapeutics-- -- -$6.3M -
What do Analysts Say About CSLLY or KZIA?
CSL has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1312.2%. Given that Kazia Therapeutics has higher upside potential than CSL, analysts believe Kazia Therapeutics is more attractive than CSL.
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL0 0 0 KZIAKazia Therapeutics0 0 0 -
Is CSLLY or KZIA More Risky?
CSL has a beta of 0.750, which suggesting that the stock is 25% less volatile than S&P 500. In comparison Kazia Therapeutics has a beta of 2.117, suggesting its more volatile than the S&P 500 by 111.748%.
-
Which is a Better Dividend Stock CSLLY or KZIA?
CSL has a quarterly dividend of $0.73 per share corresponding to a yield of 1.53%. Kazia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL pays 47.92% of its earnings as a dividend. Kazia Therapeutics pays out -- of its earnings as a dividend. CSL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or KZIA?
CSL quarterly revenues are --, which are smaller than Kazia Therapeutics quarterly revenues of --. CSL's net income of -- is lower than Kazia Therapeutics's net income of --. Notably, CSL's price-to-earnings ratio is 32.13x while Kazia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL is 5.69x versus -- for Kazia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL5.69x 32.13x -- -- KZIAKazia Therapeutics-- -- -- --
-
Which has Higher Returns CSLLY or MESO?
Mesoblast has a net margin of -- compared to CSL's net margin of --. CSL's return on equity of 14.06% beat Mesoblast's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL-- -- $29.9B MESOMesoblast-- -- -- -
What do Analysts Say About CSLLY or MESO?
CSL has a consensus price target of --, signalling downside risk potential of --. On the other hand Mesoblast has an analysts' consensus of $11.00 which suggests that it could grow by 30.06%. Given that Mesoblast has higher upside potential than CSL, analysts believe Mesoblast is more attractive than CSL.
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL0 0 0 MESOMesoblast0 0 0 -
Is CSLLY or MESO More Risky?
CSL has a beta of 0.750, which suggesting that the stock is 25% less volatile than S&P 500. In comparison Mesoblast has a beta of 3.357, suggesting its more volatile than the S&P 500 by 235.658%.
-
Which is a Better Dividend Stock CSLLY or MESO?
CSL has a quarterly dividend of $0.73 per share corresponding to a yield of 1.53%. Mesoblast offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL pays 47.92% of its earnings as a dividend. Mesoblast pays out -- of its earnings as a dividend. CSL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or MESO?
CSL quarterly revenues are --, which are smaller than Mesoblast quarterly revenues of --. CSL's net income of -- is lower than Mesoblast's net income of --. Notably, CSL's price-to-earnings ratio is 32.13x while Mesoblast's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL is 5.69x versus 179.39x for Mesoblast. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL5.69x 32.13x -- -- MESOMesoblast179.39x -- -- --
-
Which has Higher Returns CSLLY or OPT?
Opthea has a net margin of -- compared to CSL's net margin of --. CSL's return on equity of 14.06% beat Opthea's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL-- -- $29.9B OPTOpthea-- -- $65.7M -
What do Analysts Say About CSLLY or OPT?
CSL has a consensus price target of --, signalling downside risk potential of --. On the other hand Opthea has an analysts' consensus of $12.17 which suggests that it could grow by 212.37%. Given that Opthea has higher upside potential than CSL, analysts believe Opthea is more attractive than CSL.
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL0 0 0 OPTOpthea5 0 0 -
Is CSLLY or OPT More Risky?
CSL has a beta of 0.750, which suggesting that the stock is 25% less volatile than S&P 500. In comparison Opthea has a beta of 0.710, suggesting its less volatile than the S&P 500 by 29.036%.
-
Which is a Better Dividend Stock CSLLY or OPT?
CSL has a quarterly dividend of $0.73 per share corresponding to a yield of 1.53%. Opthea offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL pays 47.92% of its earnings as a dividend. Opthea pays out -- of its earnings as a dividend. CSL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or OPT?
CSL quarterly revenues are --, which are smaller than Opthea quarterly revenues of --. CSL's net income of -- is lower than Opthea's net income of --. Notably, CSL's price-to-earnings ratio is 32.13x while Opthea's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL is 5.69x versus 2,492.46x for Opthea. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL5.69x 32.13x -- -- OPTOpthea2,492.46x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
